MiMedx Group, Inc. (MDXG)
| Market Cap | 1.11B |
| Revenue (ttm) | 246.47M |
| Net Income (ttm) | -88.36M |
| Shares Out | 111.72M |
| EPS (ttm) | -0.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $9.94 |
| Previous Close | $9.72 |
| Change ($) | 0.22 |
| Change (%) | 2.26% |
| Day's Open | 9.81 |
| Day's Range | 9.70 - 9.95 |
| Day's Volume | 291,748 |
| 52-Week Range | 5.32 - 12.87 |
BATON ROUGE, La., May 4, 2021 /PRNewswire/ -- Prescience Point Capital Management ("Prescience Point"), a research-focused, catalyst-driven investment firm that is the beneficial owner of approximately ...
Questions Every Shareholder Should Ask Prescience Point
Urges Shareholders to Vote the WHITE Proxy Card “FOR ALL” Four of MIMEDX's Director Nominees – Dr. Kathleen Behrens, Mr. Todd Newton, Mr. Timothy Wright, and Dr. Phyllis Gardner
First Quarter Net Sales of $60.0 Million
Accomplished Regulatory Leader Joins MiMedx Management Team
MARIETTA, Ga., April 22, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, ...
Advances Potential for Use of Micronized Dehydrated Human Amnion Chorion Membrane (mdHACM) as a Safe and Effective Treatment Option
No Shareholder Action Required at This Time
BATON ROUGE, La., April 16, 2021 /PRNewswire/ -- Prescience Point Capital Management, together with its affiliates ("Prescience Point"), a research-focused, catalyst-driven investment firm, announced to...
MARIETTA, Ga., March 30, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing birth tissue as a platform for regenerative medicine, tod...
Noted biopharmaceutical thought leader adds academic, research and industry expertise
Fourth Quarter Net Sales of $68.5 million, Full Year 2020 Net Sales of $248.2 million
MARIETTA, Ga., March 02, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today anno...
MARIETTA, Ga., Feb. 10, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today annou...
Persistent and sustained institutional buying in MiMedx should not be ignored as heavy hitters position themselves for key knee osteoarthritis data in 2021. Sales and revenue growth after two years of f...
Significant evidence indicates that Amniofix is a highly effective and safe treatment for knee OA, and that the product will likely receive FDA approval for this indication. The RMAT designation further...
Experienced Healthcare Executive Will Expand Company's Visibility Within the Financial Community
MARIETTA, Ga., Nov. 24, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today annou...
MiMedx Group is in the early stages of a sales recovery, after a turbulent last 2 years. 90% of management are new faces, and the new growth strategy dovetails to include commercialization, R&D focus an...
MARIETTA, Ga., Nov. 13, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today provi...
MARIETTA, Ga., Nov. 12, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today annou...
MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q3 2020 Results - Earnings Call Transcript
Third Quarter Net Sales of $64 . 3 M illion , Above Preliminary Range
MARIETTA, Ga., Nov. 03, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today con...
Only Amniotic Product Covered Under Updated Commercial Policy
MARIETTA, Ga., Oct. 30, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today ann...
MARIETTA, Ga., Oct. 29, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today ann...
MARIETTA, Ga., Oct. 15, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and a therapeutic biologics company, today ann...
Research Advances Understanding of Amniotic Tissue as Potential Unique Treatment for Painful Chronic Condition that Affects 242 Million People Globally
Third Quarter 2020 Net Sales Expected to be Between $61 Million - $64 Million
Research in Plantar Fasciitis Advances Understanding of Amniotic Tissue as Potential Treatment for Chronic Musculoskeletal Pain and Function Disorders
New Allograft Expands to Twice its Size and Provides a Protective Structure to Support the Wound Healing Cascade
MARIETTA, Ga., Aug. 24, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics compan...
MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q2 2020 Results - Earnings Call Transcript
Pharmaceutical and Biotech Executive to Focus on Product and Pipeline Development Priorities Pharmaceutical and Biotech Executive to Focus on Product and Pipeline Development Priorities
Second Quarter Net Sales of $53.6 million
Strategic Leader with Proven Record of Delivering Growth and Business Transformation Strategic Leader with Proven Record of Delivering Growth and Business Transformation
MiMedx Fixes Cash Concerns With Relisting Right Around The Corner
Company Now Caught Up in Financial Reporting
Annual Report on Form 10-K includes Audited Financial Results for 2019
Equity Financing Led by EW Healthcare Partners and Debt Financing Provided by Hayfin Capital Management
March Flowers Could Bring MiMedx Showers Of Shareholder Returns
MiMedx Group Inc. MDXG, +0.08% said Tuesday it has reached a settlement with the Securities and Exchange Commission to resolve a probe of its accounting practices.
10 Reasons To Buy MiMedx Stock Today
A timetable of upcoming catalysts points to impressive upside potential by the end of 2019 and the beginning of 2020.
August starts the watch for restatements of MiMedx's financials possibly right before the company's yet to be scheduled 2019 Annual Meeting.
The beleaguered company has made significant progress in the last two months to right the ship but the shorts continue to press with a thesis that has drifted substantially.
The beleaguered company has made significant progress in the last two months to right the ship but the shorts continue to press with a thesis that has drifted substantially.
The beleaguered company has made significant progress in the last two months to right the ship but the shorts continue to press with a thesis that has drifted substantially.
Annual meeting on June 17th will be an inflection point for the company with former CEO Petit either embraced or shunned by MiMedx shareholders.
About MDXG
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers,... [Read more...]
| Industry Medical Devices | |
| Stock Exchange NASDAQ | Ticker Symbol MDXG |
Financial Performance
In 2020, MiMedx Group's revenue was $248.23 million, a decrease of -17.05% compared to the previous year's $299.26 million. Losses were -$83.33 million, 225.8% more than in 2019.
Analyst Forecasts
The average 12-month stock price forecast for MiMedx Group is 18.00, which is an increase of 81.09% from the latest price.